Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Lufax Holding Ltd — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B), while Lufax Holding Ltd trades at $0.96 (market cap $1.01B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 5.8× Lufax Holding Ltd's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Lufax Holding Ltd for 13 Days on average.
| IOVA | LU | |
|---|---|---|
Market Cap | $5.85B | $1.01B |
Volume | 14,517,176 | 4,754,976 |
Sector | Health | Financials |
52-Week High | $14.82 | $3.93 |
52-Week Low | $1.81 | $0.95 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $5.78B | $59.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LU trades at $0.98, down 2.83% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and declining revenue trends. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Analyst consensus remains predominantly bullish with 69% buy ratings, citing deep value potential despite ongoing operational challenges.
LU presents a high-risk, event-driven opportunity with significant valuation discounts (P/S 0.26, P/B 0.07) but faces substantial execution risks amid regulatory pressures and persistent losses. The stock's outlook hinges on successful restructuring and potential Hong Kong listing catalysts, though near-term headwinds from China's consumer lending sector remain challenging for profitability recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
